P2, N=13, Terminated, Spanish Breast Cancer Research Group | Trial completion date: Aug 2026 --> May 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> May 2025; The study was closed early due to safety concerns and an unfavorable benefit-risk balance. Unexpected high neutropenia rates required a costly sub-study, which was not feasible, forcing the sponsor to terminate the trial prematurely.

P2, N=24, Active, not recruiting, Shanghai Pulmonary Hospital, Shanghai, China

Our study provides a prognostic assessment tool for GC based on EMT-related genes and offers novel insights into understanding the roles of EMT in GC progression and treatment resistance. These findings may aid in the development of precision therapy strategies for GC.

P2, N=30, Not yet recruiting, Xijing Hospital

Dual HER2-targeted therapy combined with chemotherapy is a promising strategy for HER2-positive mCRC patients with good performance status. This approach warrants validation in large-scale clinical trials to confirm its efficacy.

Both HER2 and ESR1 are determinant of KN026 efficacy in advanced HER2-positive breast cancer, implying the potential of KN026 combined with endocrine therapy in HER2- and ER-positive breast cancer.

Chemotherapy-free regimens demonstrate promising responses and survival outcomes in patients with HER2-positive early breast cancer. However, the combination of anti-HER2 drugs with chemotherapy still demonstrates superior overall clinical outcomes.

Among these, LTS0131923 demonstrated the highest binding affinity against HER2 (PDB ID: 7MN5), with a binding energy of -11.2 kcal/mol and an inhibition constant of 0.00626 μM, outperforming Tucatinib, a standard CRC treatment. This study reveals the potential of ML-driven approaches to accelerate the discovery of dual-target inhibitors for CRC therapy and highlights Ceratonia siliqua L. as a promising source of bioactive compounds for cancer treatment.

The developed 2D-LC analytical method not only demonstrates good precision, accuracy, recovery, and stability, but also is simple, rapid, feasible, and practical for TDM. It can be used for the concentration monitoring of pyrotinib in clinic, providing more scientific evidence for clinical practice.

This outcome highlights the potential benefits of comprehensive approaches and the feasibility of proactive local interventions for oligoprogressive disease. This case provides valuable experience for managing similar cases and offers new ideas for combining novel modalities like antibody-drug conjugates (ADC) drugs, immunotherapy, and radiotherapy.

Large-scale phase III clinical trials are needed to verify the efficacy of combined neoadjuvant treatment application for GC.

P2, N=45, Active, not recruiting, Shanghai Zhongshan Hospital | Not yet recruiting --> Active, not recruiting